Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Receivables (2019 - 2025)

Historic Receivables for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $106.4 million.

  • Catalyst Pharmaceuticals' Receivables rose 8262.62% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 8262.62%. This contributed to the annual value of $65.5 million for FY2024, which is 2235.3% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Receivables of $106.4 million as of Q3 2025, which was up 8262.62% from $65.9 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Receivables high stood at $106.4 million for Q3 2025, and its period low was $5.6 million during Q1 2021.
  • For the 5-year period, Catalyst Pharmaceuticals' Receivables averaged around $38.3 million, with its median value being $42.8 million (2023).
  • Its Receivables has fluctuated over the past 5 years, first crashed by 1904.39% in 2021, then surged by 41460.85% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Receivables (Quarter) stood at $6.6 million in 2021, then surged by 57.71% to $10.4 million in 2022, then soared by 412.64% to $53.5 million in 2023, then grew by 22.35% to $65.5 million in 2024, then surged by 62.52% to $106.4 million in 2025.
  • Its Receivables was $106.4 million in Q3 2025, compared to $65.9 million in Q2 2025 and $71.3 million in Q1 2025.